Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events

Frailty was uncommon in these trials, and participants with a high degree of frailty were rarely included. Frailty is associated very modest attenuation of treatment efficacy for glycaemic outcomes and with greater incidence of both adverse events and MACE independent of treatment allocation. While these findings are compatible with calls to relax HbA1c-based targets in people living with frailty, they also highlight the need for inclusion of people living with frailty in trials. This would require changes to trial processes to facilitate the explicit assessment of frailty and support the participation of people living with frailty. Such changes are important as the absolute balance of risks and benefits remains uncertain among those with higher degrees of frailty, who are largely excluded from trials.

Authors

Institutions

Publication Details

Journal
PLoS Medicine
Published
2025-04-07
DOI
https://doi.org/10.1371/journal.pmed.1004553
Citations
10
Primary Topic
Frailty in Older Adults
Type
article
Field-Weighted Citation Impact
12.24

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events

Andrew Paul Clegg, Kenneth J. Rockwood, Miles D. Witham, David Phillippo et al.
10 citations
PLoS Medicine
Frailty in Older Adults
12.24
article

Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events

Andrew Paul Clegg, Kenneth J. Rockwood, Miles D. Witham, David Phillippo, Lili Wei, David McAllister, Nicky J. Welton, Elaine Butterly, Sofia Dias, Ryan McChrystal, Amanda Adler, Peter Hanlon, Heather Wightman, Naveed A. Sattar
article en
10 citations

Abstract

Frailty was uncommon in these trials, and participants with a high degree of frailty were rarely included. Frailty is associated very modest attenuation of treatment efficacy for glycaemic outcomes and with greater incidence of both adverse events and MACE independent of treatment allocation. While these findings are compatible with calls to relax HbA1c-based targets in people living with frailty, they also highlight the need for inclusion of people living with frailty in trials. This would require changes to trial processes to facilitate the explicit assessment of frailty and support the participation of people living with frailty. Such changes are important as the absolute balance of risks and benefits remains uncertain among those with higher degrees of frailty, who are largely excluded from trials.

PLoS MedicineVol. 22(4)
Dalhousie University (CA), University of Leeds (GB), Cumbria Northumberland Tyne and Wear NHS Foundation Trust (GB), Nova Scotia Health Authority (CA), University of Bristol (GB), University of Oxford (GB), Oxford Centre for Diabetes, Endocrinology and Metabolism (GB), NIHR Newcastle Biomedical Research Centre (GB), Bradford Teaching Hospitals NHS Foundation Trust (GB), University of York (GB), University of Glasgow (GB)
Medical Research Council
Good health and well-being
Openalex Percentile: Top 1%
Frailty in Older Adults
12.24
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.